2026 Medical Aesthetics M&A Market Update

OLYMPIC M&A

2026 Medical Aesthetics M&A Market Update

The Consolidation Wave Is Accelerating. What It Means for Your Practice.

The best cash-pay category in healthcare is still overwhelmingly independently owned. That is the medical aesthetics m&a opportunity.

If you own a medical aesthetics practice or med spa, you have built something increasingly rare, increasingly valuable, and increasingly sought after by sophisticated buyers.

If you own a medical aesthetics practice, you've probably asked at least one of these questions:

Is consolidation in medical aesthetics real — or just noise?
How much is my med spa actually worth in today's market?
Are buyers actually interested in a practice like mine?
What should I be doing right now to protect and maximize my options?

This report answers every one of those questions.

If you're thinking about selling your practice — or simply want to understand what it's worth before you ever have to make a decision — you're in the right place.

Medical aesthetics has never experienced a true institutional consolidation cycle at scale. That's changing now.

This med spa industry report 2026 draws on primary industry data and Olympic M&A's own deal-market analysis — not a single vendor's marketing numbers. Every credible med spa market report published this year points to the same underlying pattern: a large, fast-growing, still-fragmented category that institutional capital has only just begun to consolidate.

For the first time, private equity and platform capital are engaging this category in a meaningful, sustained way. Based on what has happened in every comparable healthcare sector before this one — dermatology, dental, veterinary, behavioral health — the window during early consolidation tends to favor prepared sellers. It does not stay open forever.

$17B+

U.S. medical spa industry revenue

American Med Spa Association, 2024–2025 State of the Industry Report

$1B+

Industry revenue growth added per year

American Med Spa Association, 2024–2025 State of the Industry Report

17.9%

Growth in med spa locations, 2022–2023 (8,899 → 10,488)

American Med Spa Association, 2024 State of the Industry Report

Your market is not a niche. It is a rapidly expanding category attracting serious institutional attention for the first time. Most owners practicing in medical aesthetics today have not yet connected what that means for the value of what they built.

Why This Moment Is Different

To understand why medical aesthetics m&a activity is accelerating, it helps to understand what makes this category structurally different from most of healthcare.

Medical aesthetics is overwhelmingly a cash-pay business. There's no payer negotiation, no prior authorization friction, no multi-year reimbursement contracting cycle standing between a treatment and the revenue it generates. That single structural fact is a large part of why capital that has spent the last decade consolidating dermatology, dental, and veterinary practices has now turned its attention here.

3–4%

Estimated share of U.S. med spas currently PE-consolidated. The vast majority of the category remains independently owned.

Olympic M&A market analysis, compiled from AmSpa 2026 industry look-back, Scope Research, FOCUS, Breakwater, Sofer, and HealthFMV

30+

Active private equity platforms currently competing for medical aesthetics acquisitions nationally.

Olympic M&A market analysis, 2026

50+/yr

Tracked medical aesthetics M&A transactions by 2023–2024, up from a handful of deals in 2019.

Olympic M&A market analysis, 2026

You don't have to take anyone's word for what's happening in medical aesthetics m&a. You can look at where the capital has actually gone. Understanding today's medical aesthetics market size is the starting point:

The Signal the Market Is Already Sending

Named, active platform sponsors are already deploying real capital into this category. This isn't speculative interest — it's committed capital, actively acquiring. The med spa acquisition news over the past two years tells a consistent story: med spa m&a is no longer a theoretical trend, and med spa acquisitions 2026 are increasingly concentrated among a small number of well-capitalized, repeat buyers.

Active Medical Aesthetics Platform Sponsors — 2026

Princeton Medspa Partners → Backed by BC Partners → Approximately $120M Deployed

Also actively acquiring: AYA Medical Spa · Shore Capital · VSS Capital · Eagle Merchant Partners

Source: Olympic M&A market analysis, 2026

Each of these sponsors is competing for the same limited pool of well-run, well-documented practices. That competition is what creates favorable terms for sellers who are actually prepared to engage.

Dermatology. Dental. Veterinary. Behavioral health. Each sector rewarded early platform sellers and punished late arrivals as multiples compressed once consolidation matured.

Medical aesthetics is now in that same early window. The owners who prepare now define their own terms. The ones who wait react to terms set by others.

What Makes Your Practice Attractive to Buyers

When a sophisticated buyer evaluates a medical aesthetics practice, they're not looking at what you see every day. They're looking at the fundamentals that make this category structurally attractive relative to the rest of healthcare — this is the core of the medical aesthetics m&a thesis, and the specific multiple your practice earns within that opportunity.

5x–9x

Typical standalone practice EBITDA multiple

AMSA 2026 industry look-back; Scope Research; FOCUS; Breakwater; Sofer; HealthFMV

10x–14x

Realized multiple once acquired into an active platform

Same sources — multiple arbitrage dynamic

+0.5x–1.0x

Premium for strong recurring membership revenue

Same sources

These numbers describe exactly what institutional buyers are looking for — predictable cash flow, low payer risk, and a business that can run without total dependence on the owner. Here's the complete picture of what buyers see when they evaluate a well-run medical aesthetics practice:

Overwhelmingly cash-pay revenue — no reimbursement risk, no payer negotiation
Recurring membership or package revenue that reduces perceived risk
Documented, transferable systems that don’t depend entirely on the owner
Clean compliance and injectable-supervision documentation
A provider bench beyond the owner — injectors, estheticians, and support staff who are retained and trained
A market where standalone practices are worth meaningfully more once folded into an active platform

When a buyer evaluates your practice, they’re not just buying revenue. They’re buying a model, a team, and predictability in a category defined by fragmentation.

And who exactly are these buyers?

Private Equity Platforms

Building medical aesthetics platforms, attracted by recurring membership revenue, cash-pay economics, and minimal insurance exposure.

MSO & Physician Groups

Acquiring practices to add locations and membership-based revenue to existing multi-site networks, often structured through an MSO in CPOM states.

Strategic Regional Buyers

Larger regional med spa groups and aesthetics-adjacent brands expanding density and filling specific geographic or service-line gaps.

Individual Operators

Physicians, nurse practitioners, and existing owners acquiring a single location to operate directly, typically using SBA or conventional financing.

Each buyer type has different motivations, different timelines, and different ideas about what a partnership actually looks like. Understanding who’s approaching your market — and what they’re specifically looking for — is one of the most important things you can do before any conversation begins.

Each buyer type has different motivations, different timelines, and different ideas about what partnership looks like. Understanding who is approaching your market — and what they are specifically looking for — is one of the most important things you can do before any conversation begins.

How Your Practice Was Valued Then — And How It Is Valued Now

If you’ve ever thought about what your practice might be worth, you probably had a number in your head — one based on how medical aesthetics practices have historically been valued: physician or owner income, rough revenue multiples, and the assumption that the most likely buyer was another individual operator.

That model is changing.

Historically, your practice would have been valued primarily on owner income and a rough revenue multiple. The buyer was typically another individual operator or a small regional group.

Medical aesthetics is now in that same early window. The owners who prepare now define their own terms. ThToday, sophisticated buyers evaluate your practice on its fundamentals — adjusted EBITDA, recurring revenue, financial clarity, and operational depth beyond the owner. That shift changes everything about how your practice is valued. e ones who wait react to terms set by others.

The number in your head may be significantly lower than what a properly run, competitive process would actually produce. That’s not an accident — it’s the result of never having seen your practice through a buyer’s eyes. That’s exactly what this report is designed to change.

What Drives the Value of Your Practice

Understanding medical aesthetics deal multiples 2026 starts with understanding that not all practices are valued equally. Two practices with similar revenue can look very different through a buyer's eyes — and that gap can be worth hundreds of thousands of dollars in outcome.

Your practice commands a stronger outcome when it demonstrates:

Stable, growing membership or package revenue — clients who renew consistently over time
Clean, defensible financials — clear adjusted EBITDA with properly documented add-backs
Operational systems that extend beyond you — the practice can function without you present
Modern EHR, scheduling, and client-engagement technology that signals scalability
Low concentration risk — no single provider, promotion, or referral source representing an outsized share of revenue
Organized injectable-supervision and provider-credentialing documentation

Practice size matters significantly. A well-prepared single-location practice with clean financials, strong recurring revenue, and documented systems typically supports valuations in the 5x to 9x adjusted EBITDA range. A multi-location platform with meaningful scale and operational depth can move meaningfully above that range, depending on buyer interest and the competitive process used to bring it to market.

Small improvements in your practice fundamentals can create substantial increases in value.

A $200,000 improvement in documented EBITDA × a 7x multiple = $1.4 million increase in the value of your practice.

Preparation directly impacts outcome. The owners who understand this early — and act on it — define their own terms.

What You Are Actually Worried About

You're probably not lying awake thinking about EBITDA multiples.

You're thinking about your clients. Your team. Your independence. What you built, and whether it will survive contact with institutional capital.

Those concerns are valid — and they're exactly the questions most generalist M&A advisors aren't equipped to answer, because they've never worked inside a medical aesthetics practice. You're probably asking some version of these:

If I partner, will a buyer interfere with how I run patient and client care?
Will my staff be treated well after a transaction?
Will corporate mandates change the culture I spent years building?
Will my clients feel like they were “sold”?
Is this buyer experienced in medical aesthetics — or learning on my practice?

These aren't questions most investment bankers focus on. They deserve direct answers from someone who has actually been on both sides of this table.

Not all capital behaves the same way.

The right partnership preserves your autonomy, strengthens your infrastructure, and protects what you built. The wrong one can quietly dismantle it. The wrong one can quietly dismantle it.

Experience in medical aesthetics — not just general healthcare M&A — is the difference.

Where Do You Want to Take Your Practice?

Not every owner reading this is thinking about selling. That's exactly the point.

You may want to grow your practice and increase its value before ever going to market
You may want to explore a partnership that lets you stay clinically active while gaining liquidity and infrastructure
You may want to plan a full transition on your terms — your timeline, your successor, your legacy
You may simply want to understand what your practice is worth right now, with no obligation, no timeline, and no pressure

Whatever your timeline, building your exit strategy early gives you options that waiting never will. The owners who start this conversation before they need to are the ones who define their own terms.

Preparation doesn't mean you're selling. It means you're in control.

Knowing what your practice is worth and what your options look like gives you leverage in any conversation — whether that conversation happens in 12 months or never.

Why 2026 Is a Defining Year

Medical aesthetics has matured as a category. The model has proven itself financially, clinically, and culturally. Clients value access and results. Owners value independence. Investors value cash-pay, recurring revenue. Understanding aesthetic medicine m&a trends heading into next year starts with recognizing that this maturity is exactly what draws institutional capital in.

When institutional capital enters a healthcare model at scale for the first time, early consolidation phases historically produce the strongest valuation environments — not because buyers are generous, but because competition among buyers is highest and the market hasn't yet established a ceiling. That's where the medical aesthetics m&a 2026 outlook sits right now, and it's consistent with what the broader medical aesthetics private equity news cycle has been reporting throughout the year.

There are specific, common mistakes owners make when approaching this moment that materially reduce their outcome — responding to an unsolicited offer without representation, going to market with unaddressed owner-dependency, and evaluating an offer on price alone without reviewing structure. We cover all three, and exactly what to do instead, in the webinar below.

The best way to sell a medical aesthetics practice is not to wait until you're ready to sell. It's to prepare while you still have time to strengthen your position — so that when the right conversation happens, you walk into it with leverage.

The most sophisticated practice owners in your position are not rushing to sell.

They are quietly preparing.
Strengthening their fundamentals.
Reducing owner dependency.
Building operational depth.
Understanding how buyers evaluate a practice like theirs.

They're positioning themselves whether they transact in 12 months or 36 months. The question is whether you're one of them.

Your Next Step

We host a private, practice-owner-only webinar covering exactly what's in this report — and the specific steps you can take right now to protect your value and your options.

If you're asking how to sell a medical aesthetics practice — or simply how to understand what yours is worth — this session is built for you. In this session you'll leave knowing:

Exactly what your practice is worth in today’s market — and what’s driving or limiting that number
The three mistakes that cost medical aesthetics owners real money — and how to avoid every one of them
What separates a high-value practice from a low-value one in the eyes of a sophisticated buyer
How to strengthen your position before any buyer approaches you — whether you transact in 12 months, 36 months, or never

This session is limited to 10 practice owners so Tony can answer your specific questions directly. It's a real conversation, not a presentation. Tony reads every question submitted before the session.

Limited to 10 practice owners per session | Confidential | No cost

Prefer a private conversation about your specific practice first? Schedule a confidential strategy call.

Want a quick estimate of your practice value? Use the medical aesthetics valuation calculator.

Send Me the Free Report

Delivered to your inbox immediately. No webinar. No sales call. No obligation.

No webinar. No sales call. No obligation. Just the most important market

intelligence available for concierge practice owners right now.

Frequently Asked Questions About Medical Aesthetics M&A in 2026

What is the size of the medical aesthetics market?

The U.S. medical spa industry has surpassed $17 billion in annual revenue and is adding more than $1 billion in revenue per year, per the American Med Spa Association's 2024–2025 State of the Industry Report. The number of med spa locations grew from 8,899 in 2022 to 10,488 in 2023.

Is there real M&A activity in medical aesthetics right now?

Yes. Med spa m&a 2026 activity builds on tracked deal volume that grew from a handful of transactions in 2019 to more than 50 per year by 2023–2024, with more than 30 active private equity platforms currently competing for acquisitions and an estimated 3–4% of med spas nationally already PE-consolidated. Med spa deals 2026 continue to favor practices that can document clean financials and recurring revenue.

What multiples do medical aesthetics deals sell for in 2026?

Standalone practices typically trade in the 5x to 9x adjusted EBITDA range, while practices acquired into an existing platform can see multiple arbitrage toward 10x to 14x. Smaller practices under roughly $1M in EBITDA are often priced on a seller's discretionary earnings basis instead.

Who is actively acquiring medical aesthetics practices?

Active platform sponsors include Princeton Medspa Partners (backed by BC Partners), AYA Medical Spa, Shore Capital, VSS Capital, and Eagle Merchant Partners, alongside a broader pool of more than 30 active acquisition platforms nationally.

Should I sell my medical aesthetics practice now or wait?

There's no universal answer — it depends on your goals, your practice's readiness, and your timeline. What the data shows is that early consolidation phases in comparable healthcare sectors have historically rewarded prepared sellers. Preparing now, even without a firm timeline, preserves your options.

About Tony Siebel

Tony Siebel is the Founder and Managing Director of Olympic M&A, a specialized concierge practice brokerage and advisory firm focused on helping concierge medicine physicians understand their options and maximize their outcomes.

As a concierge practice broker with direct experience on both sides of the transaction table, Tony brings a perspective no other advisor in this space can offer.

What makes Tony's perspective unique for concierge physicians — in the order that matters most:

The only M&A advisor in the country with direct experience acquiring concierge practices from inside the nation’s largest concierge network
Former MDVIP Corporate Development Director responsible for acquiring independent concierge practices nationally
Recruited and evaluated more than 60 concierge physicians nationwide
Advisor on $70M+ in completed healthcare M&A transactions

Tony has written extensively on healthcare consolidation, founder transitions, and strategic positioning in concierge medicine. Through Olympic M&A, he helps concierge physicians understand their options, protect what they have built, and structure partnerships that respect the physician-patient relationship.

Few M&A advisors bring direct operating and acquisition experience inside a specialized healthcare franchise to the table.

That experience is what every conversation with Tony is built on.

OLYMPIC M&A